
Opinion|Videos|January 31, 2025
Faricimab Molecular Design and Role of Ang-2
Panelists discuss how faricimab’s bispecific antibody design uniquely targets both VEGF-A and Ang-2 pathways, addressing the complementary role of Ang-2 in vascular destabilization and inflammation in retinal diseases.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What is the unique nature of the faricimab molecule, and what is the clinical rationale for targeting Ang-2 in treating retinal diseases?
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
AAVantgarde Bio closes $141 million Series B financing round
2
Monocular, High-Risk Geographic Atrophy Managing for Vision Preservation
3
4DMT releases positive interim 1.5- to 3.5-year data from phase 1/2 PRISM trial
4
Balancing Anti-VEGF and GA Therapies for Co-Treating AMD and GA in the Same Eye
5















































